SCHEMBL2102484

SCHEMBL2102484

O=C(c1ccc(-c2cc(Cl)ccc2O)cc1Cl)N1CCOCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.64
L3MBTL1 Q9Y468 1/20 0.55
HSP90AA1 P07900 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
TSHR P16473 2/20 0.51
MAPT P10636 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
LMNA P02545 2/20 0.51
EPHX2 P34913 1/20 0.48
PRKCZ Q05513 1/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HTT P42858 2/20 0.48
GAA P10253 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA3 P07451 1/20 0.48
CA4 P22748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2103604 0.89 HSP90AA1 (0.50) KDM4EHSP90AA1TSHRMEN1KMT2A
SCHEMBL9792231 0.84 KDM4E (0.77) KDM4EL3MBTL1HSP90AA1SMN1; SMN2TSHR
SCHEMBL487433 0.83 KDM4E (0.75) KDM4EL3MBTL1HSP90AA1SMN1; SMN2TSHR
SCHEMBL3529322 0.82 PIK3CA (0.44) KDM4EL3MBTL1TSHRMEN1KMT2A
SCHEMBL2103451 0.80 KDM4E (0.54) KDM4EL3MBTL1SMN1; SMN2TSHRMAPT
SCHEMBL1042677 0.79 KDM4E (1.00) KDM4EL3MBTL1HSP90AA1SMN1; SMN2TSHR
SCHEMBL4469583 0.77 TSHR (0.71) KDM4EL3MBTL1HSP90AA1SMN1; SMN2TSHR
SCHEMBL3525797 0.77 ABL1 (0.46) KDM4EHSP90AA1TSHRMEN1KMT2A
SCHEMBL2099200 0.77 HPGD (0.47) KDM4EL3MBTL1HSP90AA1TSHRLMNA
SCHEMBL20956676 0.76 KDM4E (0.68) KDM4EL3MBTL1HSP90AA1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722741-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2014-05-13 US disclosed
EP-1784388-B3 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2012-09-05 EP disclosed
US-20120178732-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease LUKER TIMOTHY JON (GB) 2012-07-12 US disclosed
US-8163727-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2012-04-24 US disclosed
US-20100160285-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2010-06-24 US disclosed
US-7737135-B2 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease ASTRAZENECA AB (SE) 2010-06-15 US disclosed
EP-1784388-B1 BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2009-11-04 EP disclosed
US-20080132480-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178732-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 KDM4E 2344/4885L3MBTL1 3961/4885HSP90AA1 891/4885
US-20100160285-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 KDM4E 2344/4885L3MBTL1 3961/4885HSP90AA1 891/4885
US-20080132480-A1 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease CYP26A1, CYP1A1, GPBAR1 KDM4E 2344/4885L3MBTL1 3961/4885HSP90AA1 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.